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Abstract 
Review on PRAME, with data on DNA/RNA, on 
the protein encoded and where the gene is 
implicated. 
Identity 
Other names: CT130, MAPE, OIP-4, OIP4 
HGNC (Hugo): PRAME 
Location: 22q11.22 
DNA/RNA 
Note 
PRAME is a member of a multigene family present 
in humans and other mammals. It was originally 
identified as a gene encoding a novel cancer-testis 
antigen that is over expressed in melanoma (Ikeda 
et al., 1997). Its evolution is consistent with 
adaptive (positive) selection similar to gene clusters 
involved in immunity and reproduction, such as the 
NALP family (Tian et al., 2009). Expression of 
PRAME has been shown to be regulated by 
hypomethylation of its promoter in AML and CML 
(Ortmann et al., 2008; Roman-Gomez et al., 2007). 
Description 
The gene is encoded on the reverse strand of 
chromosome 22 (22q11.22) covering a region of 
approximately 12 kilobases and is within the human 
immunoglobulin lambda gene locus (Kawasaki et 
al., 1997). This locus contains a large number of Vl  
gene segments which code for production of l light 
chains during B cell development and several other 
non-immunoglobulin genes, for example, tandem 
Suppressor of Hairy Wing genes 
(SUHW1/ZNF280A and SUHW2/ZNF280B) and a 
gene encoding a putative membrane glycoprotein 
(POM121L1). 
Transcription 
The NCBI database annotates five PRAME mRNA 
transcripts ranging from 2.1-2.7 kb in length (2141, 
2162, 2197, 2220, 2776 bases) which encode the 
same protein. 
Transcript (Including UTRs): 
- Position: chr22:22890123-22896603, Size: 6481, 
Total exon count: 4  
- Strand: - 
Coding region: 
- Position: chr22:22890489-22893484, Size: 2996, 
Coding exon count: 3 
Pseudogene 
The gene seems to have undergone multiple 
duplications during hominid evolution, and at least 
22 PRAME-like genes and 10 pseudogenes have 
been identified in the human genome (Birtle et al., 
2005). 
Protein 
Note 
PRAME is a leucine-rich protein of which 21.8% of 
residues are leucine or isoleucine. 
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Predicted domain structure of the human PRAME sequence highlighting Leucine Rich Repeats (LRRs). The LRRs are 
numbered and indicated by the blue arrows; residues conserved in typical LRRs are highlighted in bold. The black boxes indicate 
regions predicted to have a high probability of α-helicity, and two predicted NLS sequences are underlined. The boxed area in 
red is a region implicated in interaction with retinoic acid receptors (Wadelin et al., 2010). 
 
Description 
NP_006106 : Predicted 509 amino acid, 58 kDa 
protein. 
Expression 
PRAME is expressed at low levels in a few normal 
tissues, at intermediate level in adrenals, ovary, and 
endometrium and at high level in the testes. It has 
been shown to be overexpressed in malignant cells 
including the vast majority of primary and 
metastatic melanomas and is recognized by 
cytolytic T lymphocytes (Haqq et al., 2005). In 
PRAME-negative leukaemias the gene can be 
induced by demethylating agents (Sigalotti et al., 
2004). 
Localisation 
The protein has been observed to localise to both 
the nucleus and perinuclear regions (Tajeddine et 
al., 2005). PRAME contains several candidate 
nuclear localisation signal (NLS) sequences (See 
Figure). 
Function 
Human PRAME and its paralogues are related to 
LRR family proteins, some of which are known to 
have functions in cell immunity and signal 
transduction. It has been suggested that, like TLRs, 
PRAME may be upregulated in response to 
encounters with microbial pathogens, and may be 
involved in targeting intracellular PAMPs to the 
Golgi for ubiquitylation and processing. (Wadelin 
et al., 2013). PRAME has been reported to function 
as a repressor of retinoic acid (RA) signalling 
through interactions with retinoic acid receptors 
(RARs) and repression of the RARb2 gene (Epping 
et al., 2005; Epping et al., 2007). 
Homology 
Sequence homology and structural predictions 
suggest that PRAME is related to the leucine-rich 
repeat (LRR) family of proteins such as the Toll-
like receptors. The Oogenesins 1-4 also show 
considerable homology to PRAME and PRAME 
family members (Dade et al., 2003). 
Mutations 
Note 
Some listed in COSMIC. 
Implicated in 
Melanoma 
Note 
High levels of PRAME mRNA are present in the 
majority of primary and metastatic melanomas 
(88% and 95% respectively) (Haqq et al., 2005), 
while being absent in normal haematopoietic tissues 
including bone marrow (Oehler et al., 2009; Radich 
et al., 2006; Steinbach et al., 2002; van Baren et al., 
1998). 
Acute and chronic leukaemia, non 
Hodgkins lymphomas 
Note 
Numerous studies have reported highly elevated 
levels of PRAME in both acute and chronic 
leukaemias and non Hodgkin's lymphomas (van 
Baren et al., 1998; Matsushita et al., 2001; Oehler 
et al., 2009; Qin et al., 2009; Radich et al., 2006; 
Santamaria et al., 2008). PRAME expression has 
been suggested to be predicator for a good clinical 
outcome in childhood acute lymphoblastic 
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leukemia in addition to being a target for 
immunotherapy, and biomarker for the monitoring 
of minimal residual disease (Abdelmalak et al., 
2014). 
Neuroblastoma 
Note 
PRAME is expressed in high-stage neuroblastoma 
and associated with poor outcome (Oberthuer et al., 
2004). 
Breast cancer 
Note 
PRAME is expressed in advanced breast cancer and 
has been shown to be an independent prognostic 
factor for shortened disease-free survival (Doolan et 
al., 2008). 
Ovarian adenocarcinoma 
Note 
PRAME was found to be a biomarker and 
prognostic factor for patients with stage III serous 
ovarian adenocarcinomas (Partheen et al., 2008). 
Lung squamous cell carcinoma 
Note 
Northern blot analysis demonstrated that high 
proportion of positive tumours were shown to 
express PRAME (Ikeda et al., 1997). 
Head and neck cancer 
Note 
Reverse-transcriptase polymerase chain reaction 
(RT-PCR) showed high expression of the gene 
coding for the tumor antigen PRAME in surgical 
samples of the tumors, margins, and lymph nodes 
from patients with a diagnosis of head and neck 
carcinoma (Figueiredo et al., 2006). 
Neurological neoplasms 
Note 
PRAME has been identified as a potential CT 
antigen for medulloblastoma (Boon et al., 2003) 
and is universally expressed in high-stage 
neuroblastoma, and has been associated with poor 
outcome (Oberthuer et al., 2004). 
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